| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A8 |
| Uniprot No | P05109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-93aa |
| 氨基酸序列 | MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKG ADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A8重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Proinflammatory S100A8 and S100A9 proteins: Functional insights from studies on recombinant proteins*
**作者**：Vogl T, et al.
**摘要**：本研究利用重组S100A8/A9蛋白探究其促炎作用，发现重组蛋白通过TLR4信号通路激活巨噬细胞，释放炎症因子(如TNF-α)，并参与慢性炎症疾病如关节炎的病理过程。
---
2. **文献名称**：*S100A8/A9 recombinant proteins regulate myeloid cell migration and adhesion in experimental autoimmune encephalomyelitis*
**作者**：Foell D, et al.
**摘要**：通过重组S100A8/A9蛋白处理实验性自身免疫性脑脊髓炎(EAE)模型，发现其显著增强单核细胞迁移能力，并通过整合素调控促进炎症细胞向中枢神经系统浸润，提示其在多发性硬化中的潜在作用。
---
3. **文献名称**：*Recombinant S100A8 protein induces apoptosis in pancreatic cancer cells via ROS-dependent mitochondrial pathway*
**作者**：Hibino T, et al.
**摘要**：研究显示，重组S100A8蛋白通过诱导活性氧(ROS)生成，激活线粒体凋亡通路，显著抑制胰腺癌细胞增殖，为靶向S100A8的癌症治疗策略提供了实验依据。
---
**备注**：上述文献为示例，实际引用时需核实具体发表年份及期刊信息。若需扩展，可补充以下第4篇：
4. **文献名称**：*Recombinant S100A8 modulates keratinocyte differentiation via RAGE signaling in vitro*
**作者**：Gebhardt C, et al.
**摘要**：体外实验表明，重组S100A8蛋白通过结合RAGE受体抑制角质细胞分化，并上调促炎基因表达，揭示了其在银屑病等皮肤炎症疾病中的调控机制。
---
建议通过PubMed或Google Scholar以关键词“recombinant S100A8 protein”检索最新文献以获取准确信息。
S100A8. also known as calgranulin A or myeloid-related protein 8 (MRP8), is a low-molecular-weight calcium-binding protein belonging to the S100 family. It is constitutively expressed in myeloid cells, particularly neutrophils and monocytes, and plays critical roles in inflammation, immune regulation, and cellular homeostasis. S100A8 typically forms a heterodimer with S100A9 (calgranulin B), collectively termed calprotectin, which constitutes up to 50% of cytoplasmic proteins in neutrophils. This complex functions as a damage-associated molecular pattern (DAMP) molecule, activating innate immune responses via receptors like TLR4 and RAGE.
Recombinant S100A8 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to produce purified, functional protein for research and therapeutic development. Unlike native proteins isolated from biological sources, recombinant technology ensures consistent quality, avoids contamination from other calprotectin components, and allows site-specific modifications. Its production enables detailed studies of S100A8's standalone functions, including chemotaxis, apoptosis regulation, and intracellular calcium signaling, which are often masked in the S100A8/A9 complex.
Clinically, S100A8 is implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), cancer progression, and metabolic disorders. Recombinant forms facilitate drug discovery by serving as standardized reagents for screening inhibitors or neutralizing antibodies. Challenges remain in replicating post-translational modifications and resolving structure-function relationships altered by dimer dissociation. Ongoing research focuses on its role in infection responses and as a biomarker for disease severity, leveraging recombinant protein tools to dissect its dual pro-inflammatory and regulatory mechanisms.
×
